A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification

U. Hassan, T. Ghonge, B. Reddy, M. Patel, M. Rappleye, I. Taneja, A. Tanna, R. Healey, N. Manusry, Z. Price, T. Jensen, J. Berger, A. Hasnain, E. Flaugher, S. Liu, B. Davis, J. Kumar, K. White and R. Bashir ()
Additional contact information
U. Hassan: University of Illinois at Urbana-Champaign
T. Ghonge: University of Illinois at Urbana-Champaign
B. Reddy: Micro and Nanotechnology Lab, University of Illinois at Urbana-Champaign
M. Patel: University of Illinois at Urbana-Champaign
M. Rappleye: University of Illinois at Urbana-Champaign
I. Taneja: University of Illinois at Urbana-Champaign
A. Tanna: University of Illinois at Urbana-Champaign
R. Healey: University of Illinois at Urbana-Champaign
N. Manusry: University of Illinois at Urbana-Champaign
Z. Price: University of Illinois at Urbana-Champaign
T. Jensen: Biomedical Research Center, Carle Foundation Hospital
J. Berger: University of Illinois at Urbana-Champaign
A. Hasnain: University of Illinois at Urbana-Champaign
E. Flaugher: University of Illinois at Urbana-Champaign
S. Liu: University of Illinois at Urbana-Champaign
B. Davis: Biomedical Research Center, Carle Foundation Hospital
J. Kumar: Biomedical Research Center, Carle Foundation Hospital
K. White: Biomedical Research Center, Carle Foundation Hospital
R. Bashir: University of Illinois at Urbana-Champaign

Nature Communications, 2017, vol. 8, issue 1, 1-12

Abstract: Abstract Sepsis, a potentially life-threatening complication of an infection, has the highest burden of death and medical expenses in hospitals worldwide. Leukocyte count and CD64 expression on neutrophils (nCD64) are known to correlate strongly with improved sensitivity and specificity of sepsis diagnosis at its onset. A major challenge is the lack of a rapid and accurate point-of-care (PoC) device that can perform these measurements from a minute blood sample. Here, we report a PoC microfluidic biochip to enumerate leukocytes and quantify nCD64 levels from 10 μl of whole blood without any manual processing. Biochip measurements have shown excellent correlation with the results from flow cytometer. In clinical studies, we have used PoC biochip to monitor leukocyte counts and nCD64 levels from patients’ blood at different times of their stay in the hospital. Furthermore, we have shown the biochip’s utility for improved sepsis diagnosis by combining these measurements with electronic medical record (EMR).

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms15949 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms15949

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms15949

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().